Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Time to first occurrence of any element of the composite of cardiovascular death, myocardial infarction or recurrent ischemia through the end of the follow-up in non-ST elevation ACS.
Composite of cardiovascular death, myocardial infarction, or severe recurrent ischemia. Safety of long-term treatment with ranolazine compared to placebo; safety endpoints are death from any cause and symptomatic documented arrhythmia.
18 Years and older (Adult, Senior)
CVT 3036 MERLIN TIMI 36
December 21, 2004
November 26, 2009
The TIMI Study Group Boston, Massachusetts, United States
† Study has passed its completion date and status has not been verified in more than two years.